Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients~* Aged 18-65 who meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder (MDD)~* Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score of at least 22 at visits 1 and 2~* Have a Clinical Global Impressions of Severity Scale (CGI-S) score of at least 4 at visits 1 and 2~* Have a degree of understanding such that the patient can provide informed consent, complete protocol required assessments and communicate intelligibly with the investigator and study coordinator.~Exclusion Criteria:~* Patients judged clinically to be at serious suicidal risk in the opinion of the investigator~* Patients who have any prior history of bipolar disorder, psychosis, or schizophrenia~* Patients who have any current (within the past six months) DSM-IV-TR primary Axis I disorder other than MDD~* Patients with uncontrolled narrow-angle glaucoma~* Patients who have a serious medical illness that is in the opinion of the investigator not stabilized or is likely to require intervention, hospitalization, or use of an excluded medication during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
- B (Type: PLACEBO_COMPARATOR): placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).